

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	: Timothy J. Guzi et al.	Group Art Unit: To Be Assigned
Serial No::	10/654,168	Examiner: To Be Assigned
Filed:	09/03/2003	Attorney Docket No.: OC01619k
For:	NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS	•

## INFORMATION DISCLOSURE STATEMENT AND SUBMISSION OF INTERNATIONAL SEARCH REPORT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:


Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references are attached were filed in related application U.S. Serial No(s), respectively.						
(b)	No fee	is believed due because:				
			nformation Disclosure Statement is being filed within three (3) s of the filing date of the application.			
			formation Disclosure Statement is being concurrently filed with ove-identified application.			
			formation Disclosure Statement is being concurrently filed with uest for Continued Examination (RCE).			
	$\boxtimes$		nformation Disclosure Statement is being filed prior to the gof a first Office Action on the merits.			
(c)		This Information Disclosure Statement is being filed before the madate of any final action, notice of allowance or an action that other closes prosecution; and				
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
			No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or			
			The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.			

Serial No. <u>10/654,168</u> March 19, 2004 Page 2 of 2

OIPE	(d) 🗌		ormation Disclosure Statement is being filed on or before the t of the issue fee; and
MAR 2 2 2004  RADEMAR	6 302	 fo . n	Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- 5		S oo k	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
			The Commissioner is hereby authorized to charge the requisite ee listed on the attached Fee Transmittal Sheet.
	required for	this Inforr	nereby authorized to charge any additional fees which may be mation Disclosure Statement, or credit any overpayment to <u>9-0365,</u> Patent Case No. <u>OC01619K</u> .
			Respectfully submitted, SCHERING-PLOUGH CORPORATION
Date	ed: <b>March 19, 2</b> 0	004	By:
Sch	ERING-PLOUGH C nt Department, I	ORPORATI	Name: Palaiyur S. Kalyanaraman
2000 "Keni	) Galloping Hill R lworth, NJ 0703	Road 3-0530	Attorney of Record Telephone No.: (908) 298-5068
Facs	imile No.: (908)	298-5388	3

Attorney Docket No.: OC01619K

PTO/SB/92 (08-03) (Modified)



Application No.: 10/654,168 Filing Date: 09/03/2003

Applicant: Timothy J. Guzi et al.

Title: "Novel Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors"

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Signature

Palaiyur S. Kalyanaraman, Reg. No. 34,634

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

Certificate of Mailing - 1pg.

Information Disclosure Statement - 2pgs.

PTO-1449 Form - 1pg. in duplicate

References (5)

Copy of International Search Report - 3pgs.

Post Card

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

/	OIPE
PH.	MAR 2 2 2004 53

Sheet	1	of	1

	7						Sneet _	<u>1</u> or _	1
FORM PO	FORM PO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: OC01619K		APPLICATION NO.: 10/654,168		
INFO	ORM	IATION DISCLOS BY APPLIC		EMENT	APPLICAN Timothy J	T: J. Guzi et al.			
	(Use several sheets if necessary)			FILING DATE: 09/03/2003		GROUP:			
			U.S. PAT	ENT DOCU	MENTS				- · · <u>-</u>
*EXAMINER		DOCUMENT	DATE	N	AME	CLASS		FILING	
INITIAL	ļ.,	NUMBER	ļ	ļ			CLASS	APPRO	PRIATE
	AA							ļ	· · - · · · · · · · · · · · · · · · · ·
	AB							<del> </del>	
	AC AD							ļ	
-	AE		ļ <u>.</u>	<u> </u>			-	-	
	AF				<del> </del>			<del> </del>	
	AG		<del> </del>				1	<u> </u>	
	AH					+		<del> </del>	<del> </del>
	Ai							<u> </u>	
	AJ			1		1		<u> </u>	
	AK						<u> </u>	· · · · · ·	
	.1		OREIGN P	ATENT DO	CLIMENTS		<u></u>	.l	
	T	DOCUMENT	DATE	COUNTRY	JOIVILITIO	CLASS	SUB-	TRANS	LATION
		NUMBER				02,100	CLASS	YES	INO
	AL	DE 102 23 917 A1	12/11/2003	Gei	many				
	АМ	EP 1 334 973 A	08/13/2003		rope		<u> </u>	<u> </u>	
	AN	WO 03/091256	11/06/2003		IPO			1	
	AO						<u> </u>		
	AP								1
	ОТ	HER DOCUMENT	ΓS (Including	g Author, Tit	le, Date, P	ertinent Pa	ages, Et	c.)	
•	AQ	Nathanael Gray et a Chem., 6(9): 859-87				dependent Ki	nases", C	Current N	Med.
	AR								
	AS								
	AT								
	AU			· · · · · · · · · · · · · · · · · · ·					
	AV								
EXAMINER	₹		•	DATE	CONSIDERE	D			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.